Utility of FDG-PET/CT in primary central nervous system lymphoma and its contribution to prognosis estimation
Gulhane Medical Journal, cilt.59, sa.2, ss.44-48, 2018 (Scopus, TRDizin)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 59 Sayı: 2
- Basım Tarihi: 2018
- Doi Numarası: 10.5455/gulhane.271274
- Dergi Adı: Gulhane Medical Journal
- Derginin Tarandığı İndeksler: Scopus, TR DİZİN (ULAKBİM)
- Sayfa Sayıları: ss.44-48
- Anahtar Kelimeler: Disease-free survival, FDG-PET/CT, Overall survival, Primary CNS lymphoma, SUVmax
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Aims: Primary central nervous system lymphoma (PCNSL) is an aggressive form of extra-nodal non-Hodgkin's lymphoma confined to CNS at initial presentation. The role of FDG-PET/CT in PCNSL is not fully defined and reviewed systematically. This study was conducted to summarize the utility of FDG-PET/CT in the management of PCNSL and show its contribution to predicting survival. Materials and Methods: This study included 19 patients with PCNSL treated with high dose methotrexate between 2004 and 2015. We retrospectively examined PET/CT and outcome of the patients. Maximum standardized uptake value (SUVmax) was calculated. Results: Mean overall survival (OS) and disease-free survival (DFS) was 22.7 months, 16.8 months, respectively. Mean SUVmax was 19.9 ± 6.7 in recurrent/ metastatic group, 15.3 ± 7.2 in nonmetastatic (complete remission) group. There was a statistically significant difference between them according to SUVmax values (p=0.199). OS at 1st year was 84%, 58% at 2nd year. DFS at first year was 47%, 31.5% at second year. Conclusion: The utility of FDG-PET/CT can be summarized as initial diagnosis, baseline staging and restaging, evaluation of treatment response and prognosis estimation in PCNSL. SUVmax derived from FDG-PET/CT is a strong predictor for progression and survival of the disease.